CANCER HAS NO BORDERS NEITHER DO WE
BeiGene is a global, commercial-stage biotechnology company co-founded in 2010 by John Oyler, an American entrepreneur, and Dr. Xiaodong Wang, one of the youngest ever U.S. Academy of Science members and Director of China’s National Institute of Biological Sciences (NIBS) in Beijing. The two set out to build a unique company that was globally focused from its inception. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) focused on discovering, developing, manufacturing, and commercializing innovative medicines where there is global unmet need.

BeiGene’s Mission

Patients First Through Science and Affordability.
Help transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world through science and business innovation.

The BeiGene Story

A global biotechnology innovator focused on improving treatment outcomes and patient access.

Partner of Choice

Global strategic oncology collaborations to expand access to important oncology medicines for patients around the globe.

We are committed to collaborating with academia, biotech and pharmaceutical companies around the world to jointly discover and develop innovative products that will bring meaningful treatments to patients.

Amgen Collaboration:

- BeiGene commercializing three Amgen oncology products in China – XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab).
- Companies jointly developing up to 20 Amgen oncology pipeline assets globally, with BeiGene leading development in China.
- Amgen invested $2.88 billion for a 20.5% stake in BeiGene.

Novartis Collaboration:

- Novartis to co-develop and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in North America, Japan, EU, and 6 other European countries.
- BeiGene and Novartis collaborate on the development, manufacturing and commercialization of BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Japan, EU and 6 other European countries.
- BeiGene to market and promote five Novartis approved and nationally reimbursed oncology products, including TAFINLAR® (dabrafenib), MEKINIST® (trametinib), VOTRIENT® (pazopanib), AFINITOR® (everolimus), ZYKADIA® (ceritinib), in designated regions of China referred to as Broad Markets.

ADDITIONAL COLLABORATIONS

- Ambrex
- AssemblyBio
- Bristol-Myers Squibb
- Biotherics
- BiT-Tech
- EUSA Pharma
- HUCHTEN
- LEADS Biologics
- leap Therapeutics
- MEI Pharma
- Mirati Therapeutics
- Nanjing Lifetech
- Oseagen
- SpringWorks
- Strand Genomics
- Zymeworks

- 30 offices in 5 countries
- Clinical trials span 46 countries and regions
- 11 approved medicines including 1 in the U.S.
- 30+ Phase 3 or potentially registration-enabling trials

Countries and regions in which BeiGene is marketing or intends to provide therapeutics.
Cancer is relentless. Our scientists are too.

We are passionate about applying cutting-edge science to the development of life-changing therapies:

### Late-Stage Clinical Development

<table>
<thead>
<tr>
<th>Drug</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zanubrutinib</td>
<td>Second generation small molecule inhibitor of Bruton’s tyrosine kinase</td>
<td>Currently being investigated as a monotherapy and in combination with other therapies in multiple hematologic malignancies</td>
</tr>
<tr>
<td>Tislelizumab</td>
<td>Humanized IgG4 anti-PD-1 monoclonal antibody</td>
<td>Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors and hematologic malignancies</td>
</tr>
<tr>
<td>Paminarib</td>
<td>Small molecule inhibitor of PARP1 and PARP2</td>
<td>Currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors</td>
</tr>
<tr>
<td>Ociperlimab</td>
<td>Investigational TIGIT monoclonal antibody</td>
<td>Currently being investigated in combination with tislelizumab in solid tumors</td>
</tr>
</tbody>
</table>

### Early-Stage Clinical Development

<table>
<thead>
<tr>
<th>Drug</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>BGB-A445</td>
<td>Investigational OX40 against antibody</td>
<td>Currently being investigated as a monotherapy and in combination with tislelizumab in solid tumors</td>
</tr>
<tr>
<td>BGB-A425</td>
<td>Investigational humanized IgG1-variant monoclonal antibody against TIM-3</td>
<td>Currently being investigated in combination with tislelizumab in solid tumors</td>
</tr>
<tr>
<td>BGB-11417</td>
<td>Investigational small molecule Bcl-2 inhibitor</td>
<td>Currently being investigated as a monotherapy and in combination with zanubrutinib in hematologic malignancies</td>
</tr>
<tr>
<td>BGB-10188</td>
<td>Investigational phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor</td>
<td>Currently being investigated as a monotherapy, in combination with zanubrutinib in hematologic malignancies, and in combination with tislelizumab in solid tumors</td>
</tr>
<tr>
<td>Lifirafenib</td>
<td>Investigational small molecule inhibitor of the RAF protein</td>
<td>Currently being investigated as a monotherapy and in combination with other therapies in solid tumors</td>
</tr>
<tr>
<td>BGB-15025</td>
<td>Investigational hematopoietic progenitor kinase 1 (Hck) inhibitor</td>
<td>Currently being investigated as a monotherapy and in combination with tislelizumab in solid tumors</td>
</tr>
<tr>
<td>BGB-23339</td>
<td>Investigational tyrosine kinase 2 (TYK2) inhibitor</td>
<td>Currently being investigated as a monotherapy in inflammation and immunity</td>
</tr>
</tbody>
</table>

Safety and efficacy have not been established for investigational products and uses.

### Collaboration Assets

<table>
<thead>
<tr>
<th>Asset</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sotarasib</td>
<td>Investigational KRAS&lt;sup&gt;G12C&lt;/sup&gt; small molecule inhibitor</td>
<td>Currently being investigated as a monotherapy and in combination with other therapies in solid tumors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-licensed from Amgen, rights in China</td>
</tr>
<tr>
<td>Sitravatinib</td>
<td>Investigational spectrum-selective kinase inhibitor of receptor tyrosine kinases, including RET, TAM family receptors (TYRO3, Axl, HER) and split family receptors (VEGFR2, KIT)</td>
<td>Currently being investigated in combination with tislelizumab in solid tumors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-licensed from Miniti Therapeutics, rights in Asia ex-Japan, AU, NZ</td>
</tr>
<tr>
<td>Zanidatamab</td>
<td>Investigational HER2-targeted bispecific antibody</td>
<td>Currently being investigated in combination with tislelizumab in solid tumors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ</td>
</tr>
<tr>
<td>ZW49</td>
<td>Investigational HER2-targeted bispecific antibody drug conjugate (ADC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ</td>
</tr>
<tr>
<td>BGB-3245</td>
<td>Investigational RAF dimer inhibitor</td>
<td>Currently being investigated as a monotherapy in solid tumors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In collaboration with Springworks Therapeutics, rights in Asia ex-Japan</td>
</tr>
<tr>
<td>DKN-01</td>
<td>Investigational humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein</td>
<td>Currently being investigated in combination with tislelizumab in solid tumors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-licensed from LeepTherapeutics, rights in Asia ex-Japan, AU, NZ</td>
</tr>
<tr>
<td>SEA-C070</td>
<td>Investigational humanized monoclonal antibody targeting CD70</td>
<td>Currently being investigated as a monotherapy in solid hematologic malignancies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-licensed from Seagen, rights in Asia ex-Japan, AU, NZ</td>
</tr>
<tr>
<td>LBL-007</td>
<td>Investigational LAG-3 anti-LAG-3 antibody</td>
<td>Currently being investigated in combination with tislelizumab in solid tumors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-licensed from Leads Belakas, rights ex-China</td>
</tr>
</tbody>
</table>

Our Commitment

BeiGene’s commitment is to never compromise on the safety, compliance, or quality of our products, our research, or our services. We are focused on serving patients by delivering quality drug products that consistently meet or exceed all customer and regulatory requirements. Each BeiGene employee and partner is responsible for achieving our objectives and for looking at any opportunity where we can improve upon our high standards of performance.

BeiGene conducts its clinical trials in accordance with the regulatory requirements of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the China National Medical Products Administration (NMPA), as applicable. Likewise, BeiGene’s manufacturing is compliant with Good Manufacturing Practice (GMP) with its state-of-the-art manufacturing facilities and through leading manufacturing partners, including Catalent for drug product manufacturing and distribution in the U.S.

Meet Members of Our Leadership

BeiGene employees are dedicated to translating groundbreaking science into quality innovative cancer therapies, with more than 2,900 employees devoted to R&D.

John V. Oyler
Co-Founder, Chairman & CEO
BeiGene, Galeneo, Telphera, Genta, McKinsey & Company

Xiaodong Wang, Ph.D.
Co-Founder & Chairman SAB
NIBS: National Institute of Biological Sciences in Beijing, UT Southwestern Medical Center, Howard Hughes Medical Institute, National Academy of Sciences

Our U.S. Leadership

Angus Grant, Ph.D.
Chief Business Executive
Dentento Discovery Fund, Celgene

Jane Huang, M.D.
Chief Medical Officer, Hematology
Acerta, Genentech

Christian Langer, M.D.
SVP, Global Medical Affairs
AfarBio, Agio, Genentech, Bristol Myers Squibb

Jason Radford
SVP, Business Transformation
Genomic Health, Accumen, Life Technologies, DLA Piper

Josh Neiman
Chief Commercial Officer,
North America and Europe, Fibrocar Health, Onyx Pharmaceuticals, Genentech

Graham Hardiman
SVP, Global Human Resources
Pfizer, Wyeth

Melika Davis
SVP, Global Clinical Operations
SVP, Global Head of Drug Development, Quality at Novartis

Jaspreet Jaggj, M.D., Ph.D.
SVP, Clinical Portfolio Strategy
Novartis, Bristol-Myers Squibb, Pfizer, Memorial Sloan Kettering
Our employees look forward to connecting with you to provide additional insight into BeiGene.